[Management of phosphate in chronic kidney disease--Clinical trials of lanthanum carbonate].
The lanthanum carbonate which is the new phosphate binder decreased serum phosphorus value significantly in comparison with the placebo group, showed equal serum phosphorus decrease action to those at the capacity which in addition is less than calcium carbonate and sevelamer hydrochloride.
Tatsuta
Koichi
K
Wakayama Medical University, Division of Nephrology and Blood Purification Medicine.
Shigematsu
Takashi
T
D002908:Chronic Disease; D006801:Humans; D054559:Hyperphosphatemia / Q000188:drug therapy* / Q000209:etiology*; D007674:Kidney Diseases / Q000150:complications*; D007811:Lanthanum / Q000008:administration & dosage / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic
C119467:lanthanum carbonate; D007811:Lanthanum